Study summary · research use only
The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study identified BAM15, a mitochondrial uncoupling agent, through screening a small molecule compound library for effects on acute myeloid leukemia (AML) cell activity; cell-line species not specified. The abstract reports BAM15 significantly inhibited proliferation and promoted apoptosis in AML cells while showing less cytotoxicity toward normal cells, with a proposed mechanism involving disturbance of reactive oxygen species (ROS) production balance. In vivo investigations in mice found BAM15 suppressed AML progression and prolonged survival time. The authors also report BAM15 could be combined with cytarabine to enhance its anti-cancer activity and inhibit activity of primary AML cells.
Abstract
Acute myeloid leukemia (AML) is a malignant proliferative disease of myeloid hematopoietic origin and cannot be treated appropriately at present. This is due to the fact that leukemia cells are not sensitive to some of the traditional chemotherapy drugs. Or some chemotherapeutic drugs are too toxic to normal cells, affecting their wide clinical application. In this study, we identified BAM15 as a novel mitochondrial uncoupling agent by screening a library of small molecule compounds that inhibit AML cell activity. BAM15 significantly inhibited proliferation and promoted apoptosis in AML cells while at the same time being less cytotoxic to normal cells. The mechanism may be related to the disturbance of the ROS production balance. In vivo investigations revealed that BAM15 effectively suppressed AML progression and prolonged the survival time of mice. In addition, we found that BAM15 can be used in combination with cytarabine to enhance its anti-cancer activity and inhibit the activity of primary cells in AML. Therefore, we identified BAM15 as a potential drug candidate for the treatment of AML.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.